Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Hetherington, C. Andrews, Yaroslav Vaynshteyn, R. Fishel (2007)Managing follicular rash related to chemotherapy and monoclonal antibodies
Community oncology, 4
M. Lacouture (2006)Mechanisms of cutaneous toxicities to EGFR inhibitors
Nature Reviews Cancer, 6
A. Galimont-Collen, L. Vos, A. Lavrijsen, J. Ouwerkerk, H. Gelderblom (2007)Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors.
European journal of cancer, 43 5
R. Gutzmer, T. Werfel, A. Kapp, J. Elsner (2006)Kutane Nebenwirkungen einer EGF-Rezeptor-Blockade und deren Management
Der Hautarzt, 57
M. Lacouture, S. Basti, J. Patel, A. Benson (2006)The SERIES clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitors.
The journal of supportive oncology, 4 5
R. Perez-soler, J. Delord, A. Halpern, K. Kelly, J. Krueger, B. Sureda, J. Pawel, J. Temel, S. Siena, D. Soulières, L. Saltz, J. Leyden (2005)HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum.
The oncologist, 10 5
R Perez-Soler (2006)Topical vitamin K3 (menadione) prevents erlotinib and cetuximab-induced EGFR inhibition in the skin (abstract)
J Clin Oncol 2006 ASCO Annual Meeting Proceedings Part 1, 24
J. Johnston, S. Navaratnam, M. Pitz, Jerry Maniate, E. Wiechec, H. Baust, J. Gingerich, G. Skliris, L. Murphy, M. Los (2006)Targeting the EGFR pathway for cancer therapy.
Current medicinal chemistry, 13 29
Bohuslav Melichar, I. Nemcova (2007)Eye complications of cetuximab therapy.
European journal of cancer care, 16 5
M. Luu, S. Lai, J. Patel, J. Guitart, M. Lacouture (2007)Photosensitive rash due to the epidermal growth factor receptor inhibitor erlotinib
A. Scope, A. Agero, S. Dusza, P. Myskowski, J. Lieb, L. Saltz, N. Kemeny, A. Halpern (2007)Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 34
J. Bernier, J. Bonner, J. Vermorken, R. Bensadoun, R. Dummer, J. Giralt, G. Kornek, A. Hartley, R. Mesía, C. Robert, S. Segaert, K. Ang (2008)Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck.
Annals of oncology : official journal of the European Society for Medical Oncology, 19 1
N. Yamazaki, K. Muro (2007)Clinical management of EGFRI dermatologic toxicities: the European perspective.
E. Cutsem (2006)Challenges in the Use of Epidermal Growth Factor Receptor Inhibitors in Colorectal Cancer
Ki Suh, Hedy Kindler, M. Medenica, M. Lacouture (2006)Doxycycline for the treatment of paronychia induced by the epidermal growth factor receptor inhibitor cetuximab
British Journal of Dermatology, 154
S. Segaert, E. Cutsem (2005)Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors.
Annals of oncology : official journal of the European Society for Medical Oncology, 16 9
R. Perez-soler, L. Saltz (2005)Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 22
B. Guillot, D. Bessis (2006)Aspects cliniques et prise en charge des effets secondaires cutanés des inhibiteurs du récepteur à l'EGF
Annales De Dermatologie Et De Venereologie, 133
Roman Perez-Soler, Y. Zou, Tianhong Li, Maomi Li, Wancai Yang, Carmen Tornos, Y. Ling (2006)Topical vitamin K3 (Vit K3, Menadione) prevents erlotinib and cetuximab-induced EGFR inhibition in the skin.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 18_suppl
T. Lynch, Edward Kim, B. Eaby, J. Garey, D. West, M. Lacouture (2007)Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management.
The oncologist, 12 5
A. Jatoi, K. Rowland, J. Sloan, H. Gross, P. Fishkin, S. Kahanic, P. Novotny, P. Schaefer, David Johnson, L. Tschetter, C. Loprinzi (2008)Tetracycline to prevent epidermal growth factor receptor inhibitor‐induced skin rashes
M. Monti, S. Motta (2007)Clinical management of cutaneous toxicity of anti-EGFR agents.
The International journal of biological markers, 22 4
C. Robert, J. Soria, A. Spatz, A. Cesne, D. Malka, P. Pautier, J. Wechsler, C. Lhommé, B. Escudier, V. Boige, J. Armand, T. Chevalier (2005)Cutaneous side-effects of kinase inhibitors and blocking antibodies.
The Lancet. Oncology, 6 7
K. Busam, P. Capodieci, R. Motzer, T. Kiehn, D. Phelan, A. Halpern (2001)Cutaneous side‐effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225
British Journal of Dermatology, 144
S. Segaert, J. Tabernero, O. Chosidow, T. Dirschka, J. Elsner, L. Mancini, T. Maughan, J. Morere, A. Santoro, A. Sobrero, E. Cutsem, A. Layton (2005)The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 3
M Monti, S Motta (2007)Clinical management of cutaneous toxicity of anti-EGFR-agents
Int J Biol Markers, 22
Epidermal growth factor receptor (EGFR)-targeted therapies (monoclonal antibodies such as cetuximab and panitumumab as well as tyrosine kinase inhibitors like erlotinib and gefitinib) are responsible for a unique constellation of mechanism-based, class-specific side effects on the skin. Besides the well-known acneiform eruption, this skin toxicity consists of xerosis (leading to eczema and fissures), paronychia, hair changes, telangiectasia, hyperpigmentation, and mucosal changes. Dermatologic treatment is supportive and aims at maintaining quality of life while continuing EGFR-inhibitor therapy. Although a recent study demonstrated the effectiveness of prophylactic minocycline in cetuximab-induced acneiform eruption, randomized controlled trials remain sparse and evidence-based guidelines are lacking. Based on personal experience, most cases of acneiform eruption are well controlled by topical metronidazole and oral minocycline 100 mg qd. For severe reactions, minocycline dose is doubled and saline compresses have proven very valuable. For superinfection with Staphylococcus aureus, oral cefuroxim axetil can be added for a short term. Emollients and topical steroids can be administered for skin dryness or eczema. Paronychia is the hardest part to treat but antiseptic soaks and a corticosteroid paste can alleviate symptoms to some degree.
Targeted Oncology – Springer Journals
Published: Oct 1, 2008
Keywords: Acneiform eruption; Cetuximab; Epidermal growth factor receptor (EGFR); inhibitors; Erlotinib; Panitumumab; Paronychia
Access the full text.
Sign up today, get DeepDyve free for 14 days.